Get a Free 5ml Mini Now Free 5ml Mini With Every Order of The Mantle
Moumoujus

ERGOCALCIFEROL.

Avoid CAS 50-14-6 / 1406-16-2 / SKIN CONDITIONING

Ergocalciferol, also known as Vitamin D2, is an inactive vitamin D precursor derived from ergosterol. While critical for systemic health through oral administration, its topical application in skincare lacks robust clinical evidence and faces significant regulatory restrictions.

Summary

Skin conditioning Supports epidermal barrier function Anti-inflammatory properties (indirectly via active form) Aids wound healing (indirectly via active form)

Science

Mechanism of Action

As an inactive analog, Ergocalciferol undergoes a two-step hydroxylation process, first in the liver and then in the kidneys, to become its biologically active form, 1,25-dihydroxyergocalciferol (ercalcitriol). This active metabolite binds to Vitamin D receptors, modulating intracellular calcium levels. In the skin, active vitamin D is instrumental in regulating keratinocyte differentiation, thereby strengthening the epidermal barrier against external aggressors. It also contributes to the skin's innate immune response, demonstrates anti-inflammatory properties, and supports cellular processes vital for wound healing and tissue repair.

Research

Clinical Evidence

Low confidence
Effective range N/A
Optimal

N/A

Transparency

Dusting Analysis

Not commonly dusted

The Formula

Formulation

Solubility
Oil
Optimal pH N/A
0 7 14

Stability

Ergocalciferol demonstrates stability in alkaline environments but is highly susceptible to degradation by light, air (oxidation), and acidic conditions. Formulations containing this ingredient must be meticulously protected from light and air exposure. The presence of acidic components, such as alpha hydroxy acids, can lead to its inactivation.

Conflicts

  • Acidic media (e.g., hydroxy acids)
  • Air (oxidation)
  • Light (photodegradation)

Safety

Safety Profile

CIR Status
Not reviewed
Sensitization risk Unknown

The European Union strictly prohibits the use of both Ergocalciferol (Vitamin D2) and Vitamin D3 in cosmetic products under Annex II of Regulation (EC) No. 1223/2009 (No. 335). While Ergocalciferol is FDA approved for oral pharmaceutical use to address vitamin D deficiencies and related conditions, excessive oral dosages can lead to vitamin D toxicity, manifesting as hypercalcemia, increased urine output, hypertension, and kidney complications. Topical safety data for cosmetic applications is insufficient, and its regulatory status in key markets presents a significant barrier.

Your Skin

Skin Compatibility

Yes Normal
Yes Dry
Yes Oily
Yes Sensitive
Irritancy Unknown
Comedogenicity Unknown

Our Assessment

Verdict

Avoid

Due to explicit regulatory prohibition in the EU for cosmetic use and a significant lack of clinical evidence supporting its topical efficacy in skincare, Ergocalciferol is not recommended for formulation.

Related

Similar Ingredients

Finding similar ingredients…